🟢 GT Biopharma is trading 5.17% up in pre-market after broader U.S. markets opened higher

GT Biopharma is trading 5.17% up at $7.53 after broader U.S. equity markets opened higher in pre-market trading.

• The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average are each up more than 0.5%, supporting a risk-on backdrop.
• No new company-specific announcement for September 21, 2026 was identified.
• Investors remain focused on the September 15 financing, which raised dilution concerns, alongside FDA clearance for GTB-5550’s multiple-myeloma trial.